Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
May 19, 2021 17:03 ET
|
Sensei Biotherapeutics
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10...
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
May 12, 2021 07:41 ET
|
Sensei Biotherapeutics
- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head...
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
May 05, 2021 08:05 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next...
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
April 05, 2021 08:00 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next...
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update
March 25, 2021 08:00 ET
|
Sensei Biotherapeutics
-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in...
Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index
March 22, 2021 08:00 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next...
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
March 09, 2021 08:30 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...
Sensei Biotherapeutics Announces Closing of Initial Public Offering
February 10, 2021 16:55 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
February 03, 2021 20:44 ET
|
Sensei Biotherapeutics
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...